Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Top Five Deals Of 2015 (And A Few That Fell Apart)

This article was originally published in Scrip

Executive Summary

It's obvious which transaction (or pending transaction) is deal of the year for 2015 even without being told, right? Of course, it's the $160bn merger between Pfizer Inc. and Allergan PLC, not just because it will create the biggest pharma company and the biggest health care company in the world, but also because of the deals that had to occur for the merger to make sense and because of the deals that may follow on its heels in 2016.

You may also be interested in...



Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Amgen Faces Potential Lack Of Near-Commercial Assets

Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.

Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.

Topics

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel